ENGN Stock Overview
Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
enGene Holdings Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.00 |
52 Week High | US$47.17 |
52 Week Low | US$6.69 |
Beta | -0.64 |
1 Month Change | -33.92% |
3 Month Change | -46.59% |
1 Year Change | -15.81% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -8.72% |
Recent News & Updates
Recent updates
Shareholder Returns
ENGN | US Biotechs | US Market | |
---|---|---|---|
7D | 5.9% | 0.2% | 1.2% |
1Y | -15.8% | 7.4% | 20.5% |
Return vs Industry: ENGN underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: ENGN underperformed the US Market which returned 20.5% over the past year.
Price Volatility
ENGN volatility | |
---|---|
ENGN Average Weekly Movement | 11.3% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ENGN's share price has been volatile over the past 3 months.
Volatility Over Time: ENGN's weekly volatility has decreased from 29% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2023 | 32 | Jason Hanson | www.engene.com |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Holdings Inc. Fundamentals Summary
ENGN fundamental statistics | |
---|---|
Market cap | US$441.01m |
Earnings (TTM) | -US$106.80m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs ENGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENGN income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$106.80m |
Earnings | -US$106.80m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.42 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 36.1% |
How did ENGN perform over the long term?
See historical performance and comparison